Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| Prostacyclin (PGI2, epoprostenol) AGONIST at the prostanoid IP receptor (mec_id 666, target CHEMBL1995); direct_interaction and disease_efficacy true. ATC B01AC09; natural_product TRUE; parenteral only. | Crush | 12012 | No trauma translation | |
| PTH(1-34), teriparatide Parathyroid hormone receptor agonist (AGONIST), direct interaction; recombinant hPTH(1-34) | Fracture · Other | 22015–2016 | No trauma translation | |
| Puerarin Nutraceutical | Other · Spinal cord injury +3 | 62013–2020 | Not approved | |
| Putrescine combined with Schwann cell implantation Putrescine (polyamine); no curated ChEMBL mechanism record | Spinal cord injury | 12015 | Not approved | |
| Pycnogenol, pine bark extract Nutraceutical | Wound | 12017 | Not approved | |
| Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | TBI · Spinal cord injury | 22018 | No trauma translation | |
| Quipazine maleate Drug | Spinal cord injury | 12016 | Not approved | |
| Racemic nilvadipine and the (-)-nilvadipine enantiomer ARC031 Dihydropyridine L-type calcium channel blocker. | TBI | 12020 | Not approved | |
| Rapamycin (sirolimus) FK506-binding protein 1A inhibitor (INHIBITOR) | Spinal cord injury · TBI +3 | 152010–2020 | No trauma translation | |
| Recombinant activated protein C (rAPC) Coagulation factor VIII inhibitor (INHIBITOR); Coagulation factor V inhibitor (INHIBITOR) | Spinal cord injury · Ischaemia-reperfusion | 22016–2017 | Failed | |
| Recombinant human bone morphogenetic protein-2 (rhBMP-2) Recombinant human BMP-2 protein; ChEMBL get_mechanism returned SIX records, all AGONIST, all direct_interaction and disease_efficacy true (mec_id 9669 BMPR1A CHEMBL5275, 9677 BMPR1B CHEMBL5476, 9672 BMPR2 CHEMBL5467, 9680 ACVR1 CHEMBL5903, 9678 ACVR2A CHEMBL5616, 9671 ACVR2B CHEMBL5466). USAN stem -ermin (-otermin), 2001, defined as bone morphogenetic protein growth factors. ATC M05BC01. EMA cross-references Inductos (human) and Truscient (veterinary). Approved 2002, withdrawn_flag FALSE, black_box_warning FALSE, therapeutic_flag TRUE, dosed_ingredient TRUE. | Spinal cord injury · Wound | 12009–2011 | Approved for trauma | |
| Recombinant human brain-derived neurotrophic factor (BDNF) Biologic | Crush | 12012 | Not approved | |
| Recombinant human decorin Biologic | Wound · TBI +1 | 42010–2020 | Not approved | |
| Recombinant human erythropoietin (rhEPO) Erythropoietin receptor agonist (AGONIST; direct interaction) | Spinal cord injury · TBI +7 | 222004–2020 | No trauma translation | |
| Recombinant human insulin-like growth factor-1 (hIGF-1) Insulin-like growth factor I receptor agonist (AGONIST) | TBI · Haemorrhage/shock +1 | 32018–2020 | No trauma translation | |
| Recombinant uricase (rasburicase) Uric acid oxidative enzyme (OXIDATIVE ENZYME) | Haemorrhage/shock | 12020 | No trauma translation | |
| Reparixin Interleukin-8 receptor A (CXCR1) and B (CXCR2) modulator (MODULATOR) | Spinal cord injury | 12010 | Not approved | |
| Resveratrol Nutraceutical | Chemical/toxin · Radiation +7 | 192003–2020 | Not approved | |
| Retigabine KCNQ (Kv7) potassium channel opener | Spinal cord injury · TBI | 22019–2020 | No trauma translation | |
| RGFP966 Drug | Crush | 12017 | Not approved | |
| Riluzole Sodium channel alpha subunit blocker (BLOCKER) | Spinal cord injury · Crush | 62000–2020 | No trauma translation | |
| Rolipram Phosphodiesterase 4 inhibitor (INHIBITOR, direct interaction) | Spinal cord injury · TBI +1 | 52012–2019 | Not approved | |
| Rose Bengal (RB1) and derivatives modified with hydrocarbon (RB2) or polyethylene glycol (RB3) Drug | Spinal cord injury | 12018 | No trauma translation | |
| Rosiglitazone Peroxisome proliferator-activated receptor gamma agonist | Wound · Ischaemia-reperfusion +4 | 92011–2020 | Failed | |
| Ruthenium red (mitochondrial calcium uniporter inhibitor); spermine PARTIAL: spermine matched in ChEMBL as a natural polyamine (max_phase 0.5, therapeutic_flag false); get_mechanism returned 0 records, an explicit negative result. Ruthenium red returned 0 ChEMBL hits; its reported activity as a mitochondrial calcium uniporter inhibitor comes from the source literature, not ChEMBL. ClinicalTrials.gov searched for both agents: all hits were term collisions (SMS text-messaging and small-mobile-stem-cell studies) and were rejected, so zero trials is a deliberate filtered decision, not an omission. | Haemorrhage/shock · Ischaemia-reperfusion | 22014–2017 | Not approved | |
| SB-612111 (NOP receptor antagonist) Drug | TBI | 12016 | Not approved | |
| Sciatic peripheral nerve block with ropivacaine Sodium channel alpha subunit blocker (BLOCKER) | Wound · Other | 32016–2019 | No trauma translation | |
| Sclerostin antibody (rat Scl-Ab, 36.5 mg/ml, Amgen) Sclerostin inhibitor; inhibits sclerostin, increasing bone formation and decreasing bone resorption | Spinal cord injury | 22015–2018 | No trauma translation | |
| Sesame oil Nutraceutical | Crush | 12016 | Not approved | |
| Sesamin Nutraceutical | Wound | 12020 | Not approved | |
| Sevoflurane Halogenated inhalational general anaesthetic; GABA-A/glycine receptor positive modulator. | TBI | 12020 | No trauma translation | |
| Sildenafil Phosphodiesterase 5A inhibitor (INHIBITOR) | Radiation · Other +5 | 102011–2020 | No trauma translation | |
| Silodosin; phentolamine Alpha-1a adrenergic receptor antagonist (ANTAGONIST, direct interaction, disease efficacy true). | Crush | 12016 | No trauma translation | |
| Simvastatin HMG-CoA reductase inhibitor (INHIBITOR), direct interaction, disease efficacy true. | TBI · Chemical/toxin +7 | 152003–2020 | No trauma translation | |
| Siponimod S1P receptor 1/5 modulator; sequesters lymphocytes in lymph nodes. | Haemorrhage/shock | 12020 | No trauma translation | |
| Sivelestat Leukocyte elastase inhibitor (INHIBITOR; direct interaction) | Chemical/toxin · Burn +3 | 82007–2016 | Not approved | |
| Sodium bicarbonate (NaHCO3), with genetic ASIC1a deletion as a parallel intervention Drug | TBI | 12013 | No trauma translation | |
| Sodium butyrate Drug | Other · Chemical/toxin +1 | 32013–2015 | Not approved | |
| Sodium nitrite; red blood cell washing; hemopexin; TAK-242 (TLR4 inhibitor) Multi-component intervention. Sodium nitrite CHEMBL93268 (parent CHEMBL1161681), approved 2011, ATC V03AB08, black box warning, no curated ChEMBL mechanism. TAK-242 = resatorvid CHEMBL225157, max_phase 3, Toll-like receptor 4 inhibitor (target CHEMBL5255). Hemopexin (human) CHEMBL5315017 = CSL-889, max_phase 1, no curated mechanism. Red blood cell washing is a transfusion-medicine procedure with no ChEMBL entry. | Haemorrhage/shock · Crush | 22012–2015 | No trauma translation | |
| Sodium pyrophosphate (inorganic pyrophosphate, PPi) Drug | TBI | 12020 | Not approved | |
| Sodium pyruvate ChEMBL mechanism table not queried for this compound in this run; no MoA asserted. | TBI | 22011–2016 | Not approved | |
| Sodium selenate Drug | TBI | 12015 | Not approved | |
| SS31 antioxidant tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) No ChEMBL mechanism_of_action record. Cell-permeable cardiolipin-binding tetrapeptide (molecule_type Protein, max_phase 3) developed by Stealth BioTherapeutics as a mitochondria-targeted agent; ChEMBL exposes no MoA target row, so moa_list is empty. | Burn · TBI | 22011–2020 | Not approved | |
| Suberoylanilide hydroxamic acid (SAHA, vorinostat) Pan-histone deacetylase (HDAC) inhibitor; INHIBITOR action at HDAC1, HDAC2, HDAC3 and HDAC6 | Haemorrhage/shock · Ischaemia-reperfusion | 22015–2018 | No trauma translation | |
| Substance P Hormone | Ischaemia-reperfusion · Wound +1 | 32013–2019 | Not approved | |
| Sumatriptan and anti-calcitonin gene-related peptide monoclonal antibody Selective serotonin 5-HT1B and 5-HT1D receptor agonist (AGONIST; direct interaction, disease efficacy) | TBI | 32015–2020 | No trauma translation | |
| Tamoxifen Estrogen receptor alpha modulator (MODULATOR; mixed agonist/antagonist) | Spinal cord injury · Chemical/toxin | 22012–2017 | No trauma translation | |
| Tamsulosin Adrenergic receptor alpha-1 antagonist | Spinal cord injury | 12014 | No trauma translation | |
| Taurine Nutraceutical | Haemorrhage/shock | 12017 | Not approved | |
| Tauroursodeoxycholic acid (TUDCA) Unknown | Spinal cord injury · Other | 32015–2018 | No trauma translation |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.